Vanessa, a travel nurse from Memphis, Tennessee, had her life meticulously planned—building her career, saving for a home, and looking forward to a future she had worked hard to create. That all changed when she was diagnosed with stage 3 triple-negative breast cancer, the most aggressive subtype of breast cancer. The diagnosis forced her to halt her professional trajectory and focus entirely on treatment. Even as a nurse, Vanessa found herself navigating unfamiliar territory. 'I've taken care of patients my whole life,' she says, 'But I didn't really know what breast cancer truly entailed.'
Treatment began quickly, but months later, Vanessa received devastating news: the cancer had spread, and she now had metastatic triple-negative breast cancer. 'When I found out I had metastatic breast cancer, it was just an awful feeling to know you have to go through treatment again,' she recalls. Triple-negative breast cancer tends to grow and spread more rapidly than many other types. For about half of women with metastatic triple-negative breast cancer, the first treatment may be the only chance to keep the cancer from growing, making the initial choice critical. This subtype also disproportionately affects younger women and has higher incidence rates in Black and Hispanic women, underscoring the urgency of accessible education and treatment options.
Historically, treatment for metastatic triple-negative breast cancer was limited to chemotherapy, which impacts cancer cells more than normal cells but can be harsh. However, a newer class of medicine called antibody-drug conjugates (ADCs) offers a more targeted approach. Unlike traditional chemotherapy, ADCs are designed to find specific markers and deliver medicines directly to cancer cells. Until recently, ADCs were reserved for later lines of therapy, but now they may be used as a first-line treatment after diagnosis. Innovations like ADCs have already made a difference for many patients by helping to keep cancer from growing. For Vanessa, this means being able to better plan ahead, knowing her good days and bad days—whether that's the next girls' trip or time with her family.
However, not all ADCs are the same; safety and efficacy can vary. While not every patient will be eligible, understanding when they may be considered and how treatment can impact daily life can help patients feel more informed when discussing options with their care team. Dr. Gregory Vidal, Vanessa's medical oncologist and Director of Clinical Research at West Cancer Center, emphasizes the importance of considering patients' goals, wishes, and needs. 'When selecting treatment, it's important to consider patients' goals, wishes and needs so that we can try to realistically plan around those,' he says. 'All patients are different and may qualify for different ADCs.' Dr. Vidal encourages patients to have open conversations and ask questions about treatment goals at their stage of care.
Every person's experience is different, but many living with metastatic breast cancer remain on treatment for life, aiming to manage the disease and slow progression while maintaining quality of life. Vanessa leaned on her close friends and family to keep 'faith over fear' by focusing on positives and planning outings around her treatments. She encourages others to stay positive, ask questions, and advocate for themselves during treatment conversations. 'You definitely have a fight in front of you, but you can get through this,' she says. 'You have to do your research and get answers.' For more on Vanessa's journey and ADC treatment, visit Expose-MBC.com/ADC.
